The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 11, 2020
Filed:
Dec. 10, 2014
Applicant:
The Regents of the University of Michigan, Ann Arbor, MI (US);
Inventors:
Max S. Wicha, Ann Arbor, MI (US);
Christophe Ginestier, Marseilles, FR;
Assignee:
THE REGENTS OF UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); A61K 31/18 (2006.01); A61K 31/337 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); A61K 31/18 (2013.01); A61K 31/337 (2013.01); A61K 45/06 (2013.01); G01N 33/574 (2013.01); G01N 33/5743 (2013.01); G01N 33/57407 (2013.01); G01N 33/57415 (2013.01); G01N 33/57434 (2013.01); G01N 33/57449 (2013.01); G01N 2333/7158 (2013.01);
Abstract
The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).